Flexion Therapeutics Profit Margin

The latest profit margin for FLXN is -100.32% as of September 2021. That compares with -153.9% in the prior-year period — up 34.8% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Flexion Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, FLXN's profit margin moved from -153.9% to -100.32% — a 34.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Flexion Therapeutics's valuation or profitability profile.

Against Healthcare companies, FLXN currently prints -100.32% for profit margin, while the sector average sits near 14.34%. That is roughly 799.4% below the sector mean. Large gaps often invite a closer look at Flexion Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Flexion Therapeutics converts resources into returns. At -100.32%, FLXN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -153.9% in the prior-year period — up 34.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting FLXN's profit margin (-100.32%), review year-over-year change from -153.9%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.